Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm

Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $211.64, moving +0.47% from the previous trading session.

Advanced Micro Devices and Biogen have been highlighted as Zacks Bull and Bear of the Day

Advanced Micro Devices and Biogen are part of Zacks Bull and Bear of the Day article.

Kevin Cook headshot

Bear of the Day: Biogen (BIIB)

Generic sales hit MS franchise and Alzheimer's treatment is slow starter: EPS forecasts down 20%

Biogen (BIIB) Plans to Start Aduhelm Confirmatory Study in May

Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.

Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates

Phreesia (PHR) delivered earnings and revenue surprises of 14.29% and 3.93%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More

Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.

Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development

Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.

Prothena (PRTA) IND Application Gets FDA Clearance for AD

Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $211.68, marking a +0.34% move from the previous day.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $206.81, marking a -0.84% move from the previous day.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed at $193.77 in the latest trading session, marking a -1.97% move from the prior day.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $198.64, marking a -1.79% move from the previous day.

Denali (DNLI) Begins Frontotemporal Dementia-Granulin Study

Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $209.45, marking a -0.84% move from the previous day.

Denali (DNLI) Q4 Loss Wider Than Expected, Revenues Lag

Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.

Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up

Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More

Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.

Sage Therapeutics (SAGE) Depression Drug Meets Goal, Stock Down

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q4 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Biotech Stock Roundup: BMY, AMGN, REGN, BIIB's Q4 Earnings & More

Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.

Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.

Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View

Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.

Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 2.11% and 4.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?